Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H20N2 |
Molecular Weight | 264.3655 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN2c3ccccc3Cc4ccccc4C2C1
InChI
InChIKey=UEQUQVLFIPOEMF-UHFFFAOYSA-N
InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
Molecular Formula | C18H20N2 |
Molecular Weight | 264.3655 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB06148Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15771415 | http://www.medicines.org.au/files/mkptolvo.pdf
Sources: https://www.drugbank.ca/drugs/DB06148
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15771415 | http://www.medicines.org.au/files/mkptolvo.pdf
Mianserin is a tetracyclic antidepressant used for the treatment of depression. It was investigated as an adjuvant for reduction of negative and cognitive symptoms of schizophrenia, as an aid for opioid detoxification therapy (where it reduced symptoms but lead to higher drop-out rate), and for the treatment of post-traumatic stress disorder (where it was ineffective). Mianserin has a broad spectrum of activity with the most potent binding to 5-HT2A, 5-HT2C, H1, alpha2A and alpha2C receptor.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
4.3 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
4.4 nM [Ki] | ||
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
1.7 nM [Ki] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
4.8 nM [Ki] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
3.8 nM [Ki] | ||
Target ID: CHEMBL304 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415 |
101.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TOVLON Approved UseFor the treatment of major depression. |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Meta-analytical studies on new antidepressants. | 2001 |
|
Effects of mirtazapine on the levels of exogenous histamine in the plasma of the cat. | 2001 |
|
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. | 2001 |
|
Mirtazapine and bone marrow suppression: a case report. | 2001 Aug |
|
m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. | 2001 Dec |
|
First report of mirtazapine-induced arthralgia. | 2001 Dec |
|
Relative safety of mirtazapine overdose. | 2001 Dec |
|
Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. | 2001 Dec 1 |
|
Effects of voluntary ethanol intake on the expression of Ca(2+) /calmodulin-dependent protein kinase IV and on CREB expression and phosphorylation in the rat nucleus accumbens. | 2001 Dec 21 |
|
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. | 2001 Fall |
|
A review of the pharmacological and clinical profile of mirtazapine. | 2001 Fall |
|
[Postoperative pain syndrome and its relationship with individual psychological features of personality]. | 2001 Jul-Aug |
|
Effect of antidepressants on ATP-dependent calcium uptake by neuronal endoplasmic reticulum. | 2001 Nov |
|
Peripheral edema associated with mirtazapine. | 2001 Nov |
|
The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. | 2001 Nov |
|
[Interference in the serotoninergic and noradrenergic system. Faster out of depression]. | 2001 Nov 1 |
|
Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. | 2001 Nov-Dec |
|
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. | 2001 Oct |
|
Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold. | 2001 Oct |
|
Serotonin syndrome induced by fluvoxamine and mirtazapine. | 2001 Oct |
|
Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs. | 2001 Oct |
|
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. | 2001 Oct |
|
Mirtazapine versus fluoxetine in the treatment of panic disorder. | 2001 Oct |
|
Mirtazapine treatment of obsessive-compulsive disorder. | 2001 Oct |
|
Treatment of mood-congruent psychotic depression with imipramine. | 2001 Oct |
|
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001 Oct |
|
Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. | 2001 Sep |
|
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. | 2001 Sep |
|
[Toxicological analysis in the dawn of the third millenium]. | 2001 Sep-Oct |
|
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. | 2002 |
|
Mirtazapine overdose with benign outcome. | 2002 Apr |
|
PET evaluation of a tetracyclic, atypical antidepressant, [N-methyl-11C]mianserin, in the living porcine brain. | 2002 Apr |
|
Serotonin syndrome and atypical antipsychotics. | 2002 Apr |
|
Severe serotonin syndrome induced by mirtazapine monotherapy. | 2002 Apr |
|
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. | 2002 Apr |
|
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed. | 2002 Apr |
|
Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets. | 2002 Apr 15 |
|
[Unexpected drug-interaction]. | 2002 Feb |
|
Imipramine, mianserine and maprotiline block delayed rectifier potassium current in ventricular myocytes. | 2002 Feb |
|
Intravenous mirtazapine in the treatment of depressed inpatients. | 2002 Feb |
|
Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? | 2002 Feb-Apr |
|
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. | 2002 Jan |
|
Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression. | 2002 Jan 31 |
|
Successful treatment of recurrent brief depression with reboxetine -- a single case analysis. | 2002 Mar |
|
Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. | 2002 Mar |
|
Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study. | 2002 Mar |
|
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. | 2002 Mar |
|
Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release. | 2002 May |
|
Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. | 2002 May-Jun |
|
Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. | 2002 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicines.org.au/files/mkptolvo.pdf
The initial dosage of Tolvon should be judged individually. It is recommended that treatment begins with a daily dose of 30mg given in three divided doses or a single bedtime dose and be adjusted weekly in the light of the clinical response. The effective daily dose for adult patients usually lies between 30mg and 90mg (average 60mg) in divided doses or as a single bedtime dose. A maximum daily dose of 120mg should not be exceeded.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15771415
Binding of mianserin to 5-HT2A receptor was measured using radioligand binding assay, using [125I]R91150 as a radioligand, and cloned human receptors. pKi for displacement of R91150 was 4.3 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 02:34:11 UTC 2021
by
admin
on
Sat Jun 26 02:34:11 UTC 2021
|
Record UNII |
250PJI13LM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C72900
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
||
|
WHO-ATC |
N06AX03
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
||
|
WHO-VATC |
QN06AX03
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL6437
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
DB06148
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
2543
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
Mianserin
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
4184
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
6929
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | RxNorm | ||
|
246-088-6
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
1796
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
M7521
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | Merck Index | ||
|
C87209
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
D008803
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
MIANSERIN
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
135
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
24219-97-4
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
SUB08939MIG
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
7182
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
250PJI13LM
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY | |||
|
24219-97-4
Created by
admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Metabolizing reaction by CYP2D6: O-demethylation
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Pharmacological action: Tricyclic antidepressant drug (TCA)
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
The plasma concentration of the compound was within the predicted therapeutic range in only 43% of patients.
AMOUNT ADMINISTERED
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |